Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19

Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19

Clinical thoracic ultrasound plays an important role in the exploration, diagnosis and follow-up of thoracic pathologies.

The COVID (Coronavirus Disease) epidemic is leading to a large influx of patients in the emergency department with respiratory disorders. The rapid diagnosis of respiratory disorders in infected patients is important for further management.

Chest ultrasound has already demonstrated its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.

However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.

Study Overview

• Status: Completed
• Conditions: COVID-19; Pneumonia, Viral
• Intervention / Treatment: Other: No special intervention

Detailed Description

Chest ultrasound has already shown its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.

However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.

Peng reported data from 20 patients and compared them to chest CT. The abnormalities are a thickening of the pleuropneumonia line, an interstitial syndrome with B lines, corresponding to frosted glass opacities, confluent B lines (snowstorm appearance) corresponding to interstitial infiltrate, sub-pleural alveolar opacities corresponding to sub-pleural condensations, more frank alveolar images corresponding to alveolar opacities. A multifocal aspect was associated with involvement of more than 2 lobes. However, the frequency of these abnormalities as well as the sensitivity of the echo are not detailed in this article.

Another Italian article describes a clinical case of COVID-19 pneumonia with sub-pleural involvement and irregularity of the pleuro-pulmonary line.

Clinical thoracic ultrasound has a major potential interest during the COVID epidemic: available at the patient's bedside, avoiding the need to move around, feasible for the physician during his visit, easy to clean especially if ultraportable devices are used, fast and not exposing the staff any more than the usual clinical examination.

In order to determine whether this technique is useful in the management of infected patients or patients suspected of COVID-19 infection with respiratory signs, we propose a descriptive prospective study evaluating the ultrasound semiology of COVID-19 pneumonia and the interest of ultrasound in the evolutionary follow-up of these patients.

• Study Type: Observational
• Enrollment (Actual): 106

Contacts and Locations

Study Locations

• France
  • Amiens, France, 80054
    • CHU Amiens
  • Bayonne, France, 64109
    • CH de la Côte Basque
  • Boulogne-Billancourt, France, 92104
    • CHU Ambroise Pare
  • Caen, France, 14033
    • CHU caen
  • Chambéry, France, 73000
    • CHG de Chambery
  • Créteil, France, 94000
    • Centre Hospitalier Intercommunal de Créteil
  • Limoges, France, 87000
    • CHU de Limoges
  • Marseille, France, 13015
    • Aphm - Hopital Nord
  • Nancy, France, 54035
    • Chu de Nancy
  • Nîmes, France, 30029
    • CHU Nîmes
  • Orléans, France, 45100
    • CHR Orléans
  • Paris, France, 75679
    • CHU Cochin
  • Poitiers, France, 86021
    • CHU Poitiers
  • Rouen, France, 76038
    • CHU Rouen
  • Saint-Quentin, France, 02321
    • CH Saint-Quentin
  • Toulouse, France, 31059
    • CHU Larrey - Toulouse
  • Tours, France, 37000
    • CHU de Tours

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 105 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patient admitted to hospital with proven COVID-19 infection with respiratory signs and who need an hospitalization

Description

Inclusion Criteria:

• Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan

Exclusion Criteria:

• Patient not agreeing to have his or her data collected for the study
• Unconscious patient

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patient hospitalised with COVID-19 infection; Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan	Other: No special intervention; No special intervention : Ultrasound data will be collected

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Characteristics of pulmonary ultrasound for Covid-19 patients	description of ultrasound abnormalities for Covid-19 patients	Day one

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Characteristics of pulmonary ultrasound for Covid-19 patients	description of ultrasound abnormalities for Covid-19 patients	Day 3
Characteristics of pulmonary ultrasound for Covid-19 patients	description of ultrasound abnormalities for Covid-19 patients	Day 14
Charateristics of pulmonary CT-scan for Covid-19 patients	description of CT-scan abnormalities for Covid-19 patients	Day 1
Charateristics of pulmonary CT-scan for Covid-19 patients	description of CT-scan abnormalities for Covid-19 patients	Day 3
Charateristics of pulmonary CT-scan for Covid-19 patients	description of CT-scan abnormalities for Covid-19 patients	Day 14

Collaborators and Investigators

• Sponsor: Centre Hospitalier Intercommunal Creteil

Study record dates

Study Major Dates

• Study Start (Actual): March 31, 2020
• Primary Completion (Actual): May 27, 2020
• Study Completion (Actual): June 30, 2020

Study Registration Dates

• First Submitted: April 1, 2020
• First Submitted That Met QC Criteria: April 9, 2020
• First Posted (Actual): April 10, 2020

Study Record Updates

• Last Update Posted (Actual): July 17, 2020
• Last Update Submitted That Met QC Criteria: July 16, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia; Lung Diseases; COVID-19; Pneumonia, Viral
• Other Study ID Numbers: COVID-ECHO

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No